Is Abcellera Biologics Stock a Good Investment?
Abcellera Biologics Investment Advice | ABCL |
- Examine Abcellera Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Abcellera Biologics' leadership team and their track record. Good management can help Abcellera Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Abcellera Biologics' business and its evolving consumer preferences.
- Compare Abcellera Biologics' performance and market position to its competitors. Analyze how Abcellera Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if Abcellera Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Abcellera Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Abcellera Biologics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Abcellera Biologics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Abcellera Biologics Stock
Researching Abcellera Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. Abcellera Biologics has Price/Earnings To Growth (PEG) ratio of 2.22. The entity recorded a loss per share of 0.63. The firm had not issued any dividends in recent years.
To determine if Abcellera Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Abcellera Biologics' research are outlined below:
| Abcellera Biologics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 38.02 M. Net Loss for the year was (146.4 M) with loss before overhead, payroll, taxes, and interest of (136.84 M). | |
| Abcellera Biologics currently holds about 868.21 M in cash with (43.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from seekingalpha.com: AbCellera Biologics Q4 2024 Earnings Preview |
Abcellera Biologics Quarterly Liabilities And Stockholders Equity |
|
Abcellera Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Abcellera Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abcellera Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Abcellera Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Abcellera Biologics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2023-08-03 | 2023-06-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2024-05-07 | 2024-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2023-11-02 | 2023-09-30 | -0.13 | -0.1 | 0.03 | 23 | ||
2022-11-08 | 2022-09-30 | 0.05 | 0.08 | 0.03 | 60 | ||
2021-11-09 | 2021-09-30 | -0.05 | -0.08 | -0.03 | 60 | ||
2024-02-20 | 2023-12-31 | -0.13 | -0.17 | -0.04 | 30 | ||
2023-02-21 | 2022-12-31 | -0.01 | -0.1 | -0.09 | 900 |
Know Abcellera Biologics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Abcellera Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abcellera Biologics backward and forwards among themselves. Abcellera Biologics' institutional investor refers to the entity that pools money to purchase Abcellera Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tang Capital Management Llc | 2024-12-31 | 2.6 M | Renaissance Technologies Corp | 2024-12-31 | 2.5 M | Federated Hermes Inc | 2024-09-30 | 2.3 M | Ubs Group Ag | 2024-12-31 | 2 M | Guardian Partners Inc. | 2024-12-31 | 1.8 M | Guardian Capital Advisors Lp | 2023-06-30 | 1.8 M | Citadel Advisors Llc | 2024-09-30 | 1.5 M | Millennium Management Llc | 2024-12-31 | 1.5 M | Norges Bank | 2024-12-31 | 1.3 M | Baker Bros Advisors Lp | 2024-12-31 | 27.5 M | Baillie Gifford & Co Limited. | 2024-12-31 | 12.2 M |
Abcellera Biologics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 862.47 M.Market Cap |
|
Abcellera Biologics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.09) | |
| Return On Capital Employed | (0.16) | (0.15) | |
| Return On Assets | (0.09) | (0.08) | |
| Return On Equity | (0.13) | (0.11) |
Determining Abcellera Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if Abcellera Biologics is a good buy. For example, gross profit margin measures Abcellera Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Abcellera Biologics' profitability and make more informed investment decisions.
Evaluate Abcellera Biologics' management efficiency
Abcellera Biologics has return on total asset (ROA) of (0.1326) % which means that it has lost $0.1326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1555) %, meaning that it created substantial loss on money invested by shareholders. Abcellera Biologics' management efficiency ratios could be used to measure how well Abcellera Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.09 this year. Return On Capital Employed is expected to rise to -0.15 this year. At this time, Abcellera Biologics' Debt To Assets are quite stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.59 | 2.03 | |
| Tangible Book Value Per Share | 3.06 | 1.70 | |
| Enterprise Value Over EBITDA | (9.55) | (9.07) | |
| Price Book Value Ratio | 1.65 | 1.57 | |
| Enterprise Value Multiple | (9.55) | (9.07) | |
| Price Fair Value | 1.65 | 1.57 | |
| Enterprise Value | 1.8 B | 1.7 B |
Abcellera Biologics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 0.419 |
Basic technical analysis of Abcellera Stock
As of the 27th of February, Abcellera Biologics shows the mean deviation of 3.32, and Risk Adjusted Performance of 0.0431. Abcellera Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Abcellera Biologics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Abcellera Biologics is priced correctly, providing market reflects its regular price of 2.92 per share. Please also double-check Abcellera Biologics total risk alpha, which is currently at 0.2266 to validate the company can sustain itself at a future point.Abcellera Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abcellera Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abcellera Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abcellera Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Abcellera Biologics' Outstanding Corporate Bonds
Abcellera Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Abcellera Biologics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Abcellera bonds can be classified according to their maturity, which is the date when Abcellera Biologics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Abcellera Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Abcellera Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0431 | |||
| Market Risk Adjusted Performance | 0.1132 | |||
| Mean Deviation | 3.32 | |||
| Semi Deviation | 3.87 | |||
| Downside Deviation | 3.96 | |||
| Coefficient Of Variation | 2111.45 | |||
| Standard Deviation | 4.21 | |||
| Variance | 17.76 | |||
| Information Ratio | 0.0465 | |||
| Jensen Alpha | 0.2015 | |||
| Total Risk Alpha | 0.2266 | |||
| Sortino Ratio | 0.0495 | |||
| Treynor Ratio | 0.1032 | |||
| Maximum Drawdown | 24.87 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 6.01 | |||
| Downside Variance | 15.7 | |||
| Semi Variance | 15.0 | |||
| Expected Short fall | (3.52) | |||
| Skewness | 0.4648 | |||
| Kurtosis | 1.45 |
| Risk Adjusted Performance | 0.0431 | |||
| Market Risk Adjusted Performance | 0.1132 | |||
| Mean Deviation | 3.32 | |||
| Semi Deviation | 3.87 | |||
| Downside Deviation | 3.96 | |||
| Coefficient Of Variation | 2111.45 | |||
| Standard Deviation | 4.21 | |||
| Variance | 17.76 | |||
| Information Ratio | 0.0465 | |||
| Jensen Alpha | 0.2015 | |||
| Total Risk Alpha | 0.2266 | |||
| Sortino Ratio | 0.0495 | |||
| Treynor Ratio | 0.1032 | |||
| Maximum Drawdown | 24.87 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 6.01 | |||
| Downside Variance | 15.7 | |||
| Semi Variance | 15.0 | |||
| Expected Short fall | (3.52) | |||
| Skewness | 0.4648 | |||
| Kurtosis | 1.45 |
Consider Abcellera Biologics' intraday indicators
Abcellera Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Abcellera Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Abcellera Biologics Corporate Filings
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 9th of October 2024 Other Reports | ViewVerify |
Abcellera Stock media impact
Far too much social signal, news, headlines, and media speculation about Abcellera Biologics that are available to investors today. That information is available publicly through Abcellera media outlets and privately through word of mouth or via Abcellera internal channels. However, regardless of the origin, that massive amount of Abcellera data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Abcellera Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Abcellera Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Abcellera Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Abcellera Biologics alpha.
Abcellera Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Abcellera Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Abcellera Biologics Maximum Pain Price Across April 17th 2025 Option Contracts
Abcellera Biologics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Abcellera Biologics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Abcellera Biologics' options.
Abcellera Biologics Corporate Management
| Andy Clark | Head Assurance | Profile | |
| Veronique Lecault | COO Director | Profile | |
| Bo Barnhart | Scientific Director | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| EdD CEC | Senior Development | Profile | |
| Paul Colussi | Site Technologies | Profile | |
| JD Esq | Chief Officer | Profile |
Already Invested in Abcellera Biologics?
The danger of trading Abcellera Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Abcellera Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Abcellera Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Abcellera Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.63) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Abcellera Biologics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.